A COMPARATIVE-ANALYSIS OF ALKYLATING AGENT AND EPIPODOPHYLLOTOXIN-RELATED LEUKEMIAS

被引：28

作者：

ELLIS, M ^{[1
]}

RAVID, M ^{[1
]}

LISHNER, M ^{[1
]}

机构：

[1] MEIR HOSP,DEPT MED,IL-44281 KEFAR SAVA,ISRAEL

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷 / 1-2期

关键词：

EPIPODOPHYLLOTOXINS; ALKYLATING AGENTS; SECONDARY LEUKEMIA;

D O I：

10.3109/10428199309054725

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This review deals with the differences between leukemias-induced by alkylating agents as opposed to a ''new form'' of treatment related leukemia due to prior exposure to epipodophyllotoxins the latter having a short treatment-disease onset interval, absence of a MDS phase, a monocytic component and cytogenetic abnormalities involving the 11q23 band. The link between the existence of oncogenes or tumor suppressor genes located on the involved portion of chromosome 11 and the development of epipodophyllotoxin-related leukemia still needs to be examined. Alkylating agents-induced leukemias have a longer treatment-disease onset interval, have a prior myelodysplastic syndrome, and are most frequent myeloblastic or myelomonocytic in nature. Karyotype analysis reveals partial or complete deletion of chromosomes no. 5 or 7. This form of leukemia is highly resistant to treatment in the majority of cases. Some of the possible molecular mechanisms of leukemogenesis are discussed.

引用

页码：9 / 13

页数：5

共 59 条

[1]

Auclerc G., Jacquillat C., Auclerc M.F., Weil M., Bernard J., Post therapeutic leukemia, Cancer, 44, pp. 2017-2025, (1979)

[2]

Kyle R.A., Second malignancies associated with che-motherapeutic agents, Semin. Oncol., 9, pp. 131-142, (1982)

[3]

Pedersen-Bjergaard J., Philip P., Tinggaard Pedersen W., Et al., Acute nonlymphocytic leukemia. preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases, Cancer, 54, pp. 452-462, (1984)

[4]

Koeffler H.P., Syndromes of acute non lymphocytic leukemia, Ann. Intern. Med., 107, pp. 748-758, (1987)

[5]

Levine E.G., Bloomfield C.D., Secondary mye-lodysplastic syndromes and leukemias, Clin. Hematol., 15, pp. 1037-1080, (1986)

[6]

Pedersen Bjergaard J., Larsen S.O., Struck J., Et al., Risk of therapy related leukemia and preleukcmia after Hodg-kin's disease, Lancet, 329, pp. 83-88, (1987)

[7]

Vaughn W.P., Karp J.E., Burke P.J., Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy, J. Clin. Oncol., 3, pp. 204-207, (1983)

[8]

Devore R., Whitlock J., Heinsworth J.D., Johnson D.H., Therapy related acute non lymphocytic leukemia with monocytic features and rearrangement of chromosome 11q, Ann. Int. Med., 110, pp. 740-742, (1989)

[9]

Whitlock J.A., Greer J.P., Lukens J.N., Epi-podophyllotoxin-related leukemia, Cancer, 68, pp. 600-604, (1991)

[10]

Hon-Pui C., Ribeiro R.C., Hancock M.L., Acute myeloid leukemia in children treated with epipodo-phyllotoxins lor acute lymphoblastic leukemia, N. Engl. J. Med, 325, pp. 1682-1687, (1991)

← 1 2 3 4 5 6 →